|Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction.|
|Jump to Full Text|
|PMID: 23349484 Owner: NLM Status: MEDLINE|
|Insulin resistance is characterized by excessive endothelial cell generation of potentially cytotoxic concentrations of reactive oxygen species. We examined the role of NADPH oxidase (Nox) and specifically Nox2 isoform in superoxide generation in two complementary in vivo models of human insulin resistance (endothelial specific and whole body). Using three complementary methods to measure superoxide, we demonstrated higher levels of superoxide in insulin-resistant endothelial cells, which could be pharmacologically inhibited both acutely and chronically, using the Nox inhibitor gp91ds-tat. Similarly, insulin resistance-induced impairment of endothelial-mediated vasorelaxation could also be reversed using gp91ds-tat. siRNA-mediated knockdown of Nox2, which was specifically elevated in insulin-resistant endothelial cells, significantly reduced superoxide levels. Double transgenic mice with endothelial-specific insulin resistance and deletion of Nox2 showed reduced superoxide production and improved vascular function. This study identifies Nox2 as the central molecule in insulin resistance-mediated oxidative stress and vascular dysfunction. It also establishes pharmacological inhibition of Nox2 as a novel therapeutic target in insulin resistance-related vascular disease.|
|Piruthivi Sukumar; Hema Viswambharan; Helen Imrie; Richard M Cubbon; Nadira Yuldasheva; Matthew Gage; Stacey Galloway; Anna Skromna; Parkavi Kandavelu; Celio X Santos; V Kate Gatenby; Jessica Smith; David J Beech; Stephen B Wheatcroft; Keith M Channon; Ajay M Shah; Mark T Kearney|
Related Documents :
|15772704 - Statins: a treatment option for chronic heart failure?
24283954 - Cardiovascular effects of neuregulin-1/erbb signaling: role in vascular signaling and a...
23843684 - Visfatin/nampt: an adipokine with cardiovascular impact.
23522374 - Effects of silk fibroin fiber incorporation on mechanical properties, endothelial cell ...
22389314 - Endothelial cell responses to micropillar substrates of varying dimensions and stiffness.
16249234 - Fundamentally different roles for lfa-1, mac-1 and alpha4-integrin in neutrophil chemot...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2013-01-24|
|Title: Diabetes Volume: 62 ISSN: 1939-327X ISO Abbreviation: Diabetes Publication Date: 2013 Jun|
|Created Date: 2013-05-24 Completed Date: 2013-08-02 Revised Date: 2014-06-10|
Medline Journal Info:
|Nlm Unique ID: 0372763 Medline TA: Diabetes Country: United States|
|Languages: eng Pagination: 2130-4 Citation Subset: AIM; IM|
|APA/MLA Format Download EndNote Download BibTex|
Chromatography, High Pressure Liquid
Endothelial Cells / drug effects*
Insulin Resistance / genetics, physiology*
Membrane Glycoproteins / genetics, metabolism*
NADPH Oxidase / genetics, metabolism*
Polymerase Chain Reaction
Vasodilator Agents / pharmacology
|090532//Wellcome Trust; G0901203//Medical Research Council; RG/08/011/25922//British Heart Foundation; RG/12/5/29576//British Heart Foundation; //British Heart Foundation; //Medical Research Council|
|0/Membrane Glycoproteins; 0/Vasodilator Agents; EC 184.108.40.206/Cybb protein, mouse; EC 220.127.116.11/NADPH Oxidase; N9YNS0M02X/Acetylcholine|
Diabetes. 2013 Dec;62(12):e30
Diabetes. 2013 Jun;62(6):1818-20 [PMID: 23704524 ]
Diabetes. 2013 Dec;62(12):e31 [PMID: 24264411 ]
Journal ID (nlm-ta): Diabetes
Journal ID (iso-abbrev): Diabetes
Journal ID (hwp): diabetes
Journal ID (pmc): diabetes
Journal ID (publisher-id): Diabetes
Publisher: American Diabetes Association
© 2013 by the American Diabetes Association.
Received Day: 20 Month: 9 Year: 2012
Accepted Day: 25 Month: 12 Year: 2012
Print publication date: Month: 6 Year: 2013
Electronic publication date: Day: 17 Month: 5 Year: 2013
Volume: 62 Issue: 6
First Page: 2130 Last Page: 2134
PubMed Id: 23349484
Publisher Id: 1294
|Nox2 NADPH Oxidase Has a Critical Role in Insulin Resistance–Related Endothelial Cell Dysfunction|
|Richard M. Cubbon1|
|Celio X. Santos2|
|V. Kate Gatenby1|
|David J. Beech1|
|Stephen B. Wheatcroft1|
|Keith M. Channon3|
|Ajay M. Shah2|
|Mark T. Kearney1|
1Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds, U.K.
2Kings College London British Heart Foundation Centre of Excellence, London, U.K.
3University of Oxford British Heart Foundation Centre of Excellence, Oxford, U.K.
|Correspondence: Corresponding author: Mark T. Kearney, email@example.com.
Insulin resistance is a multisystem disorder of energy homeostasis, cell growth, and tissue repair, which has been shown to be pivotal to the initiation and progression of type 2 diabetes (1). As a result, type 2 diabetes is characterized by a portfolio of disorders including atherosclerotic coronary artery disease, stroke, and peripheral vascular disease (2). Atherosclerosis is characterized by a deleterious change in endothelial cell phenotype, a hallmark of which is excess generation of cytotoxic concentrations of reactive oxygen species (ROS) such as superoxide and failure of endogenous vascular antioxidant systems to adequately deal with this—a scenario described as oxidative stress (3).
Several studies support a role for insulin resistance in the generation of pathophysiological concentrations of ROS and the development of premature atherosclerosis (4). Our own studies in experimental models of insulin resistance at a whole-body level and specific to the endothelium demonstrated that insulin resistance per se is a substrate for increased generation of ROS and accelerated atherosclerosis (5,6). ROS are thought to promote atherosclerosis through a number of different mechanisms including but not limited to enhanced oxidation of lipoproteins, activation of proinflammatory genes, alteration of vascular smooth muscle cell phenotype, and reduction of bioavailability of the antiatherosclerotic signaling radical nitric oxide (NO).
A major source of ROS to emerge over the last decade is NADPH oxidase (Nox) (7,8). Nox was originally identified in phagocytes where it exists as a multisubunit complex consisting of a membrane-bound cytochrome b558 and at least four cytosolic subunits, which translocate to the membrane upon activation. It is now clear that the Noxs are a family of enzymes with each isoform being distinguished by the membrane-spanning catalytic Nox or Duox subunit that transfers electrons from NADPH to molecular oxygen, termed Nox1-Nox5 (8). We have provided evidence that increased Nox-derived ROS may be a unifying mechanism underlying insulin resistance–related oxidative stress and atherosclerosis (5,6). In the current study, we aimed to examine the therapeutic potential of inhibiting Nox and, specifically, Nox2 to reduce oxidative stress and improve endothelial-dependent vasodilatation in insulin resistance.
We used male mice with endothelial-specific mutated (dominant negative) human insulin receptor (IR) overexpression (ESMIRO) or with haploinsufficiency of IR at the whole-body level (IR+/−). ESMIRO mice aged 3–5 months (when we have demonstrated higher ROS generation ) and IR+/− mice aged 6–8 months (when we have demonstrated significantly increased endothelial cell superoxide generation ) were used. All experiments were conducted under U.K. Home Office Project license no. 40/2988. Tail venous blood sampling, glucose, and insulin tolerance tests were performed as previously described (5,6).
Pulmonary endothelial cells (PECs) were isolated by immunoselection with CD146 antibody–coated magnetic beads using published method and cultured in MV2 medium (Promocell), supplemented with 10% FCS, 100 units/mL penicillin, and 100 μg/mL streptomycin (9).
To inhibit Nox acutely, PEC or aortic rings were exposed to gp91ds-tat (50 μmol/L for 30 min). For chronic inhibition, mice were implanted with osmotic mini-pumps (Alzet), containing gp91ds-tat or control peptide as previously reported (10). The pump delivered 10 mg/kg/day of drug for 28 days.
PECs were transfected with small interfering RNA (siRNA) (Nox2: GGUCUUAUUUUGAAGUGUUtt) or scrambled control using electroporation (Amaxa, Cologne, Germany) and used after 60- to 72-h RNA isolation, and reverse transcription was performed as we previously described (9). PCR primer sequences are provided in Supplementary Table 1. SYBR green–based real-time PCR was performed in an ABI prism 7900HT Sequence Detection System (Applied Biosystems).
Protein extracts were resolved on 4–12% Bis-Tris gels (Invitrogen) and transferred to polyvinylidene fluoride membranes. Blots were probed with primary antibody (Nox2 [BD Biosciences]) or β-actin (Santa Cruz) and peroxidase-conjugated secondary antibody and developed with enhanced chemiluminescence (Millipore).
Superoxide production in PECs was measured as previously described (5,6). Pellets of PECs were resuspended in PBS containing 5% FCS and 0.5% BSA, and the luminescence was measured upon addition of a nonredox cycling concentration (5 µmol/L) of lucigenin and 100 µmol/L NADPH.
Vasomotor function was assessed in aortic rings as previously described (5,6). Rings mounted in an organ bath were equilibrated at a resting tension of 3 g for 45 min before experiments. Contraction and relaxation responses were measured by cumulative addition of phenylephrine (PE) (1 nmol/L to 10 μmol/L) and acetylcholine (Ach) (1 nmol/L to 10 μmol/L); insulin-mediated vasorelaxation in rings preconstricted with PE was examined as previously reported (6,9).
With use of previously described methods, chromatographic separation was carried out with a NovaPak C18 column in a high-performance liquid chromatography (HPLC) system (Dionex). Dihydroethidium (DHE) was monitored by absorption at 245 nm, and 2-hydroxyethidium and ethidium were monitored by fluorescence detection (11).
Results are expressed as means ± SEM. All results are representative of at least three independent repeats. Comparisons were made using paired or unpaired Student t tests or repeated-measures ANOVA as appropriate; where repeated t tests were performed, a Bonferroni correction was applied. P < 0.05 was considered statistically significant.
As previously described (6), aortic relaxation to the endothelium and NO-dependent vasodilator Ach was blunted in ESMIRO mice (Fig. 1A). For examination of the effect of inhibiting Nox on this response, aortic rings were exposed to gp91ds-tat or scrambled peptide prior to the study. Gp91ds-tat significantly enhanced Ach-induced relaxation compared with scrambled peptide (Fig. 1A). Also, gp91ds-tat significantly reduced PE-induced contraction (Supplementary Fig. 1A). However, gp91ds-tat did not alter insulin resistance of ESMIRO aorta as shown by no reduction in PE-induced contraction response in gp91ds-tat pretreated rings by insulin treatment (Supplementary Fig. 1B). Superoxide production at baseline measured using lucigenin-enhanced chemiluminescence in PECs of ESMIRO was significantly greater than in wild-type cells (Fig. 1B). For examination of the effect of acute inhibition of Nox on superoxide production, PECs were exposed to gp91ds-tat. Both gp91ds-tat and nonspecific antioxidant tiron significantly reduced superoxide level in ESMIRO PECs (Fig. 1B). Baseline superoxide measured with DHE using FACS in PECs (Fig. 1C) and by HPLC in aorta (Fig. 1D) showed similar results. Blunting of the difference in superoxide levels when the endothelium of ESMIRO aorta was denuded confirmed that endothelial cells are the primary source of excessive superoxide in aorta (Supplementary Fig. 1C).
As previously described (5), IR+/− mice also had impaired Ach-induced aortic relaxation. It was improved after gp91ds-tat treatment (Fig. 1E). Gp91ds-tat treatment also improved basal NO bioavailability as shown by a significantly higher NG-monomethyl-L-arginine (L-NMMA)–mediated increase in PE-induced aortic ring contraction (Supplementary Fig. 2). Both lucigenin assay (in PECs) and DHE HPLC assay (in aorta) showed higher basal superoxide production in IR+/−, which was significantly reduced upon incubation with gp91ds-tat (Fig. 1F–H).
For further examination of the specific isoform of Nox responsible for excessive superoxide, PECs from ESMIRO mice were examined using real-time PCR and Western blotting. The data showed significantly greater expression of Nox2 mRNA and protein in ESMIRO (Fig. 2A and B) than in wild-type littermates. Expression of other Nox family genes was unchanged (Fig. 2A). While analysis of whole aorta and lung showed similar increments in Nox2 expression, spleen failed to show any difference (Supplementary Fig. 3A). In endothelium-denuded ESMIRO aorta, there was no difference in Nox2 expression (Supplementary Fig. 3B and C), establishing the localization of excessive Nox2 in aorta as the endothelium. In PECs of IR+/− also, Nox2 expression was higher (Fig. 2C). To confirm that Nox2 is the principal source of superoxide, we used siRNA to knock down Nox2 in PECs of ESMIRO. siRNA reduced NOX2 expression but had no effect on NOX4 expression (Fig. 2D and Supplementary Fig. 4). Lucigenin-enhanced chemiluminescence confirmed that Nox2 siRNA significantly reduced superoxide generation in ESMIRO PECs (Fig. 2E and F).
To investigate the therapeutic potential of longer-term inhibition of Nox, we administered gp91ds-tat or scrambled peptide to ESMIRO and IR+/− mice via osmotic mini-pump for 28 days. Gp91ds-tat had no effect on body mass, organ weight, glucose or insulin tolerance, or plasma insulin (Fig. 3A–C, E, and G and Supplementary Fig. 5). Gp91ds-tat infusion significantly enhanced Ach-induced aortic relaxation compared with scrambled peptide in ESMIRO and IR+/− (Fig. 3D and H). Gp91ds-tat had no effect on SNP-mediated vasorelaxation (data not shown). For examination of whether gp91ds-tat induces changes in expression of ROS-related genes, real-time PCR was performed on RNA isolated from lungs of ESMIRO mice infused with gp91ds-tat or scrambled peptide. There was a significant decrease in SOD1 expression in gp91ds-tat treated animals (Supplementary Fig. 6).
Gp91ds-tat is thought to be specific for Nox2 but may affect other structurally similar Nox isoforms (12). Hence, to examine the effect of specifically inactivating Nox2 we generated ESMIRO/Nox2y/− by crossing ESMIRO mice with Nox2 holoinsufficient mice (Nox2y/−). Nox2 was successfully deleted in ESMIRO/Nox2y/− as shown on both mRNA (Supplementary Fig. 7A) and protein (Fig. 4A) levels. There was no difference in behavior, grooming, body weight, organ weight, blood pressure, glucose or insulin tolerance, or plasma insulin level (Fig. 4B–D and Supplementary Fig. 7B–D). Lucigenin-enhanced chemiluminescence showed that basal superoxide level was significantly reduced in ESMIRO/Nox2y/− PECs compared with ESMIRO (Fig. 4E). HPLC assay also showed a similar result in aorta of ESMIRO/Nox2y/− mice. Aortic rings from ESMIRO/Nox2y/− mice had significantly enhanced Ach-induced relaxation compared with ESMIRO (Fig. 4G). Real-time PCR analysis of RNA isolated from ESMIRO/Nox2y/− and ESMIRO lungs showed a significant decrease in SOD1 expression in ESMIRO/Nox2y/− (Supplementary Fig. 8).
The principal findings of the present report are as follows: 1) Acute and chronic inhibition of Nox using an inhibitory peptide reduces oxidative stress and restores defective vasomotor function in complementary in vivo models of insulin resistance. 2) Acute knockdown of Nox2 reduces oxidative stress in insulin-resistant endothelial cells. 3) Deletion of Nox2 in vivo restores aortic vasomotor function and reduces oxidative stress. 4) Chronic inhibition of Nox or Nox2 has no effect on glucose homeostasis.
Both Nox2 and Nox4 are expressed in the endothelium and may contribute to ROS production. We previously demonstrated increased Nox4 mRNA expression in coronary microvascular endothelial cells from ESMIRO mice (6). Nox4 has been shown to be regulated at an mRNA level and have a unique pattern of ROS generation (13) and could therefore contribute to insulin resistance–related oxidative stress. Here, we show that specifically inhibiting Nox2 as opposed to Nox4 restored vascular function in insulin-resistant mice. This is of particular importance, as Nox4 may have favorable effects on vascular function (11) and angiogenesis (14).
This report and our previously published work now provide a unifying mechanism for the oxidative stress associated with insulin resistance. In obese mice (15) and lean mice with whole-body (5) and endothelium-specific (6) insulin resistance, we have demonstrated reduced NO bioavailability and increased superoxide generation. The principal source of superoxide was Nox. Consistent with these studies, Nox has recently emerged as a major source of superoxide in insulin-resistant humans (16,17). Despite compelling experimental evidence supporting a role for ROS in atherosclerosis, clinical trials of antioxidants have been disappointing (18). In this context, our study showing favorable effects of specifically targeting Nox2 isoform of NADPH oxidase in insulin resistance–associated endothelial cell dysfunction gains significant importance.
In conclusion, we have demonstrated that inhibiting Nox and specifically Nox2 in vivo improves endothelial cell function in mice with insulin resistance. This approach did not adversely affect glucose homeostasis. Our data establish Nox2 as an attractive target to prevent early atherosclerosis in insulin resistance.
fn2See accompanying commentary, p. .
fn1This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1294/-/DC1.
This work was supported by the British Heart Foundation and Medical Research Council.
No potential conflicts of interest relevant to this article were reported.
P.S. performed experiments, analyzed data, and wrote the manuscript. H.V. and H.I. performed experiments and analyzed data. R.M.C. contributed to discussion and reviewed and edited the manuscript. N.Y., M.G., S.G., A.S., P.K., C.X.S., V.K.G., and J.S. performed experiments and analyzed data. D.J.B., S.B.W., K.M.C., and A.M.S. contributed to discussion and reviewed and edited the manuscript. M.T.K., A.M.S., K.M.C., and S.B.W. obtained funding and designed experiments. M.T.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
|1.||Kahn SE,Hull RL,Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. NatureYear: 2006;444:840–84617167471|
|2.||Booth GL,Kapral MK,Fung K,Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. LancetYear: 2006;368:29–3616815377|
|3.||Cai H,Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ ResYear: 2000;87:840–84411073878|
|4.||Ceriello A,Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc BiolYear: 2004;24:816–82314976002|
|5.||Duncan ER,Walker SJ,Ezzat VA,et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol MetabYear: 2007;293:E1311–E131917711985|
|6.||Duncan ER,Crossey PA,Walker S,et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. DiabetesYear: 2008;57:3307–331418835939|
|7.||Bedard K,Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol RevYear: 2007;87:245–31317237347|
|8.||Drummond GR,Selemidis S,Griendling KK,Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug DiscovYear: 2011;10:453–47121629295|
|9.||Imrie H,Viswambharan H,Sukumar P,et al. Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. DiabetesYear: 2012;61:2359–236822733797|
|10.||Rey FE,Cifuentes ME,Kiarash A,Quinn MT,Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ ResYear: 2001;89:408–41411532901|
|11.||Ray R,Murdoch CE,Wang M,et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc BiolYear: 2011;31:1368–137621415386|
|12.||Yang M,Kahn AM. Insulin-stimulated NADH/NAD+ redox state increases NAD(P)H oxidase activity in cultured rat vascular smooth muscle cells. Am J HypertensYear: 2006;19:587–59216733230|
|13.||Serrander L,Cartier L,Bedard K,et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem JYear: 2007;406:105–11417501721|
|14.||Zhang M,Brewer AC,Schröder K,et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USAYear: 2010;107:18121–1812620921387|
|15.||Noronha BT,Li JM,Wheatcroft SB,Shah AM,Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. DiabetesYear: 2005;54:1082–108915793247|
|16.||Silver AE,Beske SD,Christou DD,et al. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. CirculationYear: 2007;115:627–63717242275|
|17.||Guzik TJ,Mussa S,Gastaldi D,et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. CirculationYear: 2002;105:1656–166211940543|
|18.||Guzik TJ,Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov TodayYear: 2006;11:524–53316713904|
Previous Document: Reduction of reactive oxygen species ameliorates metabolism-secretion coupling in islets of diabetic...
Next Document: Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced ob...